Recent developments in studies investigating interactions of asbestos (1332214) with cells of the immune system were reviewed. The review summarized the pulmonary toxicity of asbestos and discussed recent studies investigating the effects of asbestos on nonspecific and specific immunity, and the role of iron (7439896) and reactive oxygen species in asbestos immunotoxicity. Occupational exposure to asbestos has been associated with increased risks for a range of pulmonary diseases and is considered to be an important cause of pulmonary malignancies, malignant mesothelioma and bronchiogenic carcinoma. The major disease associated with asbestos is asbestosis, which is an interstitial pulmonary fibrosis commonly thought to represent the terminal phase of a chronic inflammatory process. The inflammatory response along with peripheral immune changes following asbestos exposure has implicated the immune system in the pathogenesis of asbestos related disease. Studies investigating the effects of asbestos on nonspecific immunity have focused on the effects of exposure on natural killer (NK) cells, pulmonary macrophages, and pulmonary epithelial cells. Studies in laboratory animals have shown that asbestos impairs NK cell mediated cytotoxicity. Occupational asbestos exposure has been shown to decrease the number of circulating NK cells and to alter the number of local or interstitial NK cells in pulmonary tissues. Other studies have suggested that epithelial cells as well as macrophages and fibroblasts may be important effector cells in the immunopathogenesis of asbestos related diseases. Experimental studies and human observations have provided evidence that asbestos impairs specific mediated immunity and that these effects may be an important predisposing factor in asbestos induced fibrosis. Asbestos fibers as a result of the presence of iron on their surface may induce generation of reactive oxygen species which modulate intracellular redox states. This can contribute to the activation of transcription factors such as nuclear-factor-kappa-B and nuclear- factor-interleukin-6 which, in turn, stimulate inflammatory cytokines.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.